UVision, the Israeli defense technology company specializing in loitering munitions, is facing fresh uncertainty as it prepares for a potential Nasdaq listing targeting a valuation of about $3.5 billion. The company’s chief financial officer, Ronny Barak, has recently left his position, according to Calcalist, marking an unusual leadership change during an active IPO process. His departure comes as weaker performance across defense stocks is complicating UVision owner Aaron Frankel’s efforts to secure the valuation he has been seeking from investors.
CFO Change During IPO Preparations
Barak’s exit comes while UVision is conducting a roadshow ahead of the proposed public offering, adding another layer of scrutiny to the company’s preparations. Eyal Rubin, the CFO of Nasdaq-listed Nasus Pharma, is expected to replace him after announcing that he will step down from his current role in September. The circumstances surrounding Barak’s departure have not been publicly clarified, leaving questions over the timing of the transition as UVision continues discussions with prospective investors.
Valuation Expectations Face Pressure
UVision is reportedly seeking a pre-money valuation of approximately $3.5 billion for its Nasdaq IPO, but market conditions are making that target increasingly difficult to achieve. Frankel had previously held talks with Israeli institutional investors regarding the sale of a 5% to 10% stake in the company before moving ahead with the US listing process. Those investors were reportedly prepared to value UVision at between $2.5 billion and $2.9 billion, but Frankel rejected the proposed range and continued pursuing a higher valuation.
Defense Stocks Lose Momentum
The broader decline in listed defense companies has since increased pressure on UVision’s valuation ambitions after a strong two-year rally across the sector. Israeli defense technology company NextVision, for example, has fallen roughly 40% on the Tel Aviv Stock Exchange from its early-March peak and is now valued at around NIS 20 billion. That correction has weakened the valuation environment for privately held defense companies, with institutional investors reportedly becoming more cautious about applying peak-sector multiples to new listings.
IPO Pricing Becomes More Challenging
According to estimates cited by Calcalist, UVision could now struggle to secure even the $2.5 billion to $2.9 billion range that Israeli institutions were previously willing to support. That would represent a significant gap between the company owner’s expectations and the valuation that public-market investors may currently be prepared to accept. The outcome of the roadshow will therefore be critical in determining whether UVision proceeds at a lower valuation, adjusts the size or timing of the offering, or continues holding out for stronger market conditions.
UVision’s Position in the Defense Market
UVision develops loitering munition systems, often referred to as suicide drones, designed to identify, track, and strike designated targets with precision. Its Hero family of systems has positioned the company within a fast-growing segment of the global defense market, where demand has risen sharply amid recent conflicts and increased military spending. That operating backdrop has supported strong investor interest in defense technology, although public-market sentiment has become less favorable as valuations across the sector normalize.
UVision’s planned Nasdaq IPO remains an important test of investor appetite for high-growth defense technology companies after the sector’s recent market pullback. The departure of its CFO, combined with growing resistance to the targeted $3.5 billion valuation, adds uncertainty at a sensitive stage of the listing process. Whether Frankel lowers his expectations or presses ahead with the existing valuation target will likely determine the timing and structure of one of the more closely watched Israeli defense IPOs currently under consideration.
Source: Calcalist